Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications

被引:0
|
作者
Sudesh Vasdev
Vicki Gill
Pawan Singal
机构
[1] Memorial University of Newfoundland,Discipline of Medicine, Faculty of Medicine, Room H
[2] University of Manitoba,4310, Health Sciences Centre
来源
关键词
Hypertension; Atherosclerosis; Advanced glycation end products; Insulin resistance; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
The vascular diseases, hypertension and atherosclerosis, affect millions of individuals worldwide, and account for a large number of deaths globally. A better understanding of the mechanism of these conditions will lead to more specific and effective therapies. Hypertension and atherosclerosis are both characterized by insulin resistance, and we suggest that this plays a major role in their etiology. The cause of insulin resistance is not known, but may be a result of a combination of genetic and lifestyle factors. In insulin resistance, alterations in glucose and lipid metabolism lead to the production of excess aldehydes including glyoxal and methylglyoxal. These aldehydes react non-enzymatically with free amino and sulfhydryl groups of amino acids of proteins to form stable conjugates called advanced glycation end products (AGEs). AGEs act directly, as well as via receptors to alter the function of many intra- and extracellular proteins including antioxidant and metabolic enzymes, calcium channels, lipoproteins, and transcriptional and structural proteins. This results in endothelial dysfunction, inflammation and oxidative stress. All these changes are characteristic of hypertension and atherosclerosis. Human and animal studies have demonstrated that increased AGEs are also associated with these conditions. A pathological role for AGEs is substantiated by studies showing that therapies that attenuate insulin resistance and/or lower AGEs, are effective in decreasing oxidative stress, lowering blood pressure, and attenuating atherosclerotic vascular changes. These interventions include lipoic acid and other antioxidants, AGE breakers or soluble receptors of AGEs, and aldehyde-binding agents like cysteine. Such therapies may offer alternative specific means to treat hypertension and atherosclerosis. An adjunct therapy may be to implement lifestyle changes such as weight reduction, regular exercise, smoking cessation, and increasing dietary intake of fruits and vegetables that also decrease insulin resistance as well as oxidative stress.
引用
收藏
页码:48 / 63
页数:15
相关论文
共 50 条
  • [1] Role of advanced glycation end products in hypertension and atherosclerosis: Therapeutic implications
    Vasdev, Sudesh
    Gill, Vicki
    Singal, Pawan
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2007, 49 (01) : 48 - 63
  • [2] Role of Advanced Glycation End Products in Carcinogenesis and their Therapeutic Implications
    Schroeter, David
    Hoehn, Annika
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (44) : 5245 - 5251
  • [3] The role of advanced glycation end products in the development of atherosclerosis
    Peppa M.
    Uribarri J.
    Vlassara H.
    Current Diabetes Reports, 2004, 4 (1) : 31 - 36
  • [4] Advanced glycation end-products and atherosclerosis
    Vlassara, H
    ANNALS OF MEDICINE, 1996, 28 (05) : 419 - 426
  • [5] Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
    Basta, G
    Schmidt, AM
    De Caterina, R
    CARDIOVASCULAR RESEARCH, 2004, 63 (04) : 582 - 592
  • [6] Role of Receptor for Advanced Glycation End Products (RAGE) in Regression of Diabetic Atherosclerosis
    Senatus, Laura M.
    Lopez-Diez, Raquel
    Liu, Jianhua
    Li, Huilin
    Daffu, Gurdip
    Li, Qing
    Rahman, Karishma
    Vengrenyuk, Yuliya
    Barrett, Tessa
    Friedman, Richard
    Ramasamy, Ravichandran
    Fisher, Edward
    Schmidt, AnnMarie
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37
  • [7] Integral Role of Receptor for Advanced Glycation End Products (RAGE) in Nondiabetic Atherosclerosis
    Uekita, Hironori
    Ishibashi, Toshiyuki
    Sugimoto, Koichi
    Shlomi, Masashi
    Yamagishi, Shoichi
    Koyama, Hidenori
    Takeishi, Yasuchika
    CIRCULATION RESEARCH, 2009, 105 (07) : E44 - E44
  • [8] Role of megalin in endocytosis of advanced glycation end products: Implications for a novel protein binding to both megalin and advanced glycation end products
    Saito, A
    Nagai, R
    Tanuma, A
    Hama, H
    Cho, KJ
    Takeda, T
    Yoshida, Y
    Toda, T
    Shimizu, F
    Horiuchi, S
    Gejyo, F
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (05): : 1123 - 1131
  • [9] Integral role of receptor for advanced glycation end products (RAGE) in nondiabetic atherosclerosis
    Uekita, Hironori
    Ishibashi, Toshiyuki
    Shiomi, Masashi
    Koyama, Hidenori
    Ohtsuka, Shukuko
    Yamamoto, Hiroshi
    Yamagishi, Shoichi
    Inoue, Hiroyoshi
    Itabe, Hiroyuki
    Sugimoto, Koichi
    Kamioka, Masashi
    Ohkawara, Hiroshi
    Wada, Ikuo
    Takeishi, Yasuchika
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2019, 65 (03) : 109 - 121
  • [10] Accumulation of Advanced Glycation End Products in Canine Atherosclerosis
    Chiers, K.
    Vandenberge, V.
    Ducatelle, R.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2010, 143 (01) : 65 - 69